MindBio Therapeutics Corp.

MBIO

CA60256C1086

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-05-31 am EDT			5-day change	1st Jan Change
0.05 ^CAD	+11.11%		-.--%	+100.00%

May. 13	MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
May. 02	Mindbio Therapeutics Corp. Announces Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3	CI

MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024

May 13, 2024 at 12:35 pm EDT

MindBio Therapeutics Corp. reported earnings results for the third quarter and nine months ended March 31, 2024. For the third quarter, the company reported net income was AUD 0.076816 million compared to net loss of AUD 0.300665 million a year ago.
For the nine months, net loss was AUD 0.151076 million compared to AUD 0.886438 million a year ago.

Latest news about MindBio Therapeutics Corp.

MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 13	CI
Mindbio Therapeutics Corp. Announces Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3	May. 02	CI
MindBio Therapeutics Corp. Announces the Regulatory Approval of A Series of Clinical Trials in Women's Health Using MB22001	Apr. 30	CI
MindBio Beginning Landmark Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	Mar. 20	MT
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	Mar. 20	CI
MindBio Therapeutics Receives Final Approval to Conduct Phase 2B Trial Microdosing Mb22001 in Patients With MDD	Mar. 04	MT
Mindbio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder	Mar. 04	CI
MindBio Therapeutics Corp. Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial	Feb. 26	CI
MindBio Therapeutics Corp. Completes World First Take Home Phase 2a Microdosing Depression Trial	Feb. 14	CI
MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder	Jan. 30	CI
MindBio Therapeutics Corp. CEO Provides End of Year Video Update on Phase 2 Clinical Trials	Dec. 20	CI
MindBio Therapeutics Corp. Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer	23-10-31	CI
MindBio Therapeutics Corp. Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial in Advanced Stage Cancer Patients	23-10-28	CI
Mindbio Therapeutics Corp. Provides Video Update on Phase 2a Depression Trial Using MB22001	23-10-24	CI
MindBio Therapeutics Corp. Announces Tenth Patient with Depression Starts Dosing MB22001 in Take Home Microdosing Trials	23-10-05	CI
MindBio Therapeutics Corp. Begins Selection of Participants for its Phase 2 Randomized Double-Blind and Placebo Controlled Clinical Trial in Advanced Stage Cancer Patients Using Microdoses of Lylergic Acid Diethylamide and Meaning Centred Psychotherapy	23-10-04	CI
MindBio Therapeutics Corp. Announces Major Genetic Discovery in Microdosing Research	23-09-05	CI
MindBio Therapeutics Corp. Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression	23-08-24	CI
Mindbio Therapeutics Corp. Receives First Batch of Mb22001 Ready for Take At Home Psychedelic Clinical Trials	23-08-18	CI
MindBio Therapeutics Corp. Starts Pre-Screening for Participant Entry into Phase 2LSD-Microdosing Clinical Trials	23-07-19	CI
MindBio Therapeutics Corp. Announces a Significant Breakthrough Based on Sleep Data Collected During Randomized Controlled Trials of LSD-Microdosing	23-06-15	CI
MindBio Therapeutics Says Microdosing Clinical Trial Reveals "Significant" Positive Effects on Quality Of Sleep	23-06-14	MT
MindBio Therapeutics Corp. Reports Breakthrough Discovery in Microdosing Clinical Trial Reveals Significant Positive Effects on Quality of Sleep	23-06-14	CI
MindBio Therapeutics Corp. Announces Two Fully Funded Phase 2 LSD-Microdosing Clinical Trials	23-06-09	CI
Mindbio Therapeutics Receives Initial Shipment of 1,000,000 Microdoses of LSD for Phase 2 Clinical Trials for Depression	23-05-31	CI

Chart MindBio Therapeutics Corp.

Duration

Period

More charts

Company Profile

MindBio Therapeutics Corp. is a biotechnology company. The Company is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. It has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. It has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The Company invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MINDBIO THERAPEUTICS CORP.	+100.00%	4.88M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B